OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
RALEIGH, N.C., Feb. 15, 2016 -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization, will release its fourth quarter and full year 2015 financial results on Thursday, Feb. 25, 2016, prior to its quarterly earnings call at 8:00 a.m. EST.
Participants may access the conference call live via webcast on the Investor Relations section of the INC Research website at investor.incresearch.com. To participate via telephone, please dial +1 877 930 8058 within the United States or +1 253 336 7551 outside the United States approximately 15 minutes prior to the scheduled start time. The conference ID for the call is 52671020.
A webcast replay will be available on the Investor Relations section of the INC Research website at investor.incresearch.com after 1:00 p.m. on Feb. 25. In addition, an audio replay will be available for one week following the call and will be accessible by dialing +1 855 859 2056 within the United States or +1 404 537 3406 outside the United States. The replay ID is 52671020.
About INC Research
INC Research (Nasdaq:INCR) is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. The Company was named “Best Contract Research Organization” in December 2015 by an independent panel for Scrip Intelligence and ranked “Top CRO to Work With” among large global CROs in the 2015 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, N.C., with operations across six continents and experience spanning more than 100 countries.
CONTACT: Investors: Ronnie Speight, +1 919 745 2745 Media: Lori Dorer, +1 513 763 1380
